R 2487
Alternative Names: R-2487Latest Information Update: 03 Nov 2023
At a glance
- Originator Rise Therapeutics
- Class Proteins
- Mechanism of Action Regulatory T-lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Rheumatoid arthritis
- Preclinical Sjogren's syndrome
Most Recent Events
- 19 Oct 2023 Phase-I clinical trials in Rheumatoid arthritis (Treatment-experienced) in USA (PO) (NCT05961592)
- 19 Oct 2023 US FDA approves IND application for R 2487 in Rheumatoid arthritis
- 27 Jul 2023 Rise Therapeutics plans a phase I trial for Rheumatoid arthritis (In adults, In the elderly) in USA (PO) in November 2023 (NCT05961592)